ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2022
Mapping chemotherapy-induced peripheral neuropathy phenotype and health-related quality of life in patients with cancer through exploratory analysis of multimodal assessment data.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 6 citations in OpenAlex.
- Serum neurofilament light chain (sNFL) as a predictive biomarker for Chemotherapy-induced peripheral neurotoxicity (CIPN): consideration of current evidence, validation steps, and barriers to CIPN biomarker implementation in clinical practice-a narrative review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Review
- Distinct Trajectories of Chemotherapy-Induced Peripheral Neuropathy in Lymphoma Survivors Treated With R-CHOP.Oncology nursing forum · 2025Article
- Preliminary evaluation of novel Bodily Attention Task to assess the role of the brain in chemotherapy-induced peripheral neurotoxicity (CIPN).Behavioural brain research · 2024Article
- Combination chemotherapy in rodents: a model for chemotherapy-induced neuropathic pain and pharmacological screening.Metabolic brain disease · 2024Article
- Wellbeing and Complementary Therapies in Breast Cancer Peripheral Neuropathy Care: A Scoping Review Focused on Foot Health.Cancers · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeChemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of anticancer treatment based on neurotoxic agents, which may affect function and health-related quality of life (HRQoL) in patients with cancer. This exploratory study aimed to identify the phenotype of CIPN and examine the association of CIPN with general symptoms and HRQoL in patients with cancer.
methodsA secondary analysis was performed on the baseline multimodal assessment data of 87 patients with cancer who participated in a randomized trial examining the effectiveness of an 8-week acupuncture protocol in managing CIPN. The data used for this study include patient-reported CIPN, general symptoms, and HRQoL, neurological examinations, and clinician-based grading of CIPN. Descriptive statistics, non-parametric tests, and hierarchical cluster analysis were used for data analysis.
resultsPatients with CIPN experienced a series of symptoms, with numbness, tingling, and discomfort in the hands and feet being the most prominent descriptors pertaining to CIPN. Increased severity of CIPN was associated with higher distress from general symptoms and lower physical well-being. These CIPN-specific and general symptoms formed five independent symptom clusters, including two sensory neuropathy symptom clusters, a sensorimotor neuropathy one, a neuro-psychological one, and an autonomic symptom cluster. Painful CIPN was significantly associated with higher symptom burden, lower physical well-being, and impaired tendon reflex. No significant difference was found between type of neurotoxic agents in symptom burden, neurological signs, and HRQoL.
conclusionResearchers and clinicians should pay attention to the characteristics and impact of CIPN from multiple aspects, so as to develop targeted interventions to meet patients' holistic needs. Painful CIPN warrants particular attention as it is associated with higher symptom burden and lower physical well-being in patients with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.